Evoke's sole treat­ment fails to evoke the FDA's con­fi­dence, as agency re­jects Gi­moti af­ter flag­ging con­cerns last month

Hav­ing out­lined a list of lin­ger­ing con­cerns with Evoke Phar­ma’s mar­ket­ing ap­pli­ca­tion for its sole drug last month, the FDA so­lid­i­fied its dis­sent with an out­right re­jec­tion, the com­pa­ny re­vealed on Tues­day.

Dave Gony­er

The treat­ment, Gi­moti, is an in­tranasal spray for­mu­la­tion of the FDA-ap­proved meto­clo­pramide de­signed to sur­mount the lim­i­ta­tions of oral ad­min­is­tra­tion in pa­tients ex­pe­ri­enc­ing di­a­bet­ic gas­tro­pare­sis — char­ac­ter­ized by slow or de­layed gas­tric emp­ty­ing — that can cause nau­sea, vom­it­ing, and ob­struc­tion in the stom­ach, thwart­ing drug ab­sorp­tion. The drug al­so specif­i­cal­ly tar­gets women, who are dis­pro­por­tion­ate­ly af­fect­ed by the con­di­tion.

Evoke has done its ut­most to drag the drug to the fin­ish line, de­spite its che­quered past. It failed a Phase III study three years ago, evis­cer­at­ing the stock. Fi­nan­cial­ly strapped, Evoke ran a se­ries of post-hoc analy­ses to con­clude that Gi­moti was ef­fec­tive among pa­tients with mod­er­ate-to-se­vere symp­toms, in­clud­ing nau­sea and up­per ab­dom­i­nal pain, in­stead of run­ning an­oth­er late-stage tri­al. The firm al­so un­veiled fresh phar­ma­co­ki­net­ic da­ta to demon­strate “sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ences in ex­po­sure be­tween men and women giv­en the same meto­clo­pramide dose.”

Al­though the FDA agreed to re­view the drug on these da­ta and analy­ses, last month the agency ap­peared ap­pre­hen­sive about Gi­moti in the ini­tial stage of its re­view, flag­ging con­cerns about chem­istry, clin­i­cal and phar­ma­col­o­gy in­for­ma­tion in­clud­ed in the drug’s ap­pli­ca­tion.

On Tues­day, Evoke $EVOK said the com­plete re­sponse let­ter (CRL) — fo­cused on con­cerns re­lat­ed to clin­i­cal phar­ma­col­o­gy and de­vice qual­i­ty — cit­ed “few­er is­sues” than the March com­mu­ni­ca­tion, and that the agency did not re­quest any new clin­i­cal da­ta or raise safe­ty con­cerns. The com­pa­ny’s shares tum­bled near­ly 35% to $1.11 in pre­mar­ket trad­ing.

“We be­lieve that the is­sues cit­ed in the CRL, which were re­lat­ed to con­cerns over re­pro­ducible dose de­liv­ery, can be ad­dressed,” said Evoke chief Dave Gony­er in a state­ment, adding that the com­pa­ny planned to meet with the agency to dis­cuss the next steps for the pro­gram.

5AM Ven­tures: Fu­el­ing the Next Gen­er­a­tion of In­no­va­tors

By RBC Capital Markets
With Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures

Key Points

Prescription Digital Therapeutics, cell therapy technologies, and in silico medicines will be a vital part of future treatment modalities.
Unlocking the potential of the microbiome could be the missing link to better disease diagnosis.
Growing links between academia, industry, and venture capital are spinning out more innovative biotech companies.
Biotech is now seen by investors as a growth space as well as a safe haven, fuelling the recent IPO boom.

Hal Barron, GSK via YouTube

What does $29B buy you in Big Phar­ma? In Glax­o­SmithK­line’s case, a whole lot of un­com­fort­able ques­tions about the pipeline

Talk about your bad timing.

A little over a week ago, GSK R&D chief Hal Barron marked his third anniversary at the research helm by taking a turn at the virtual podium during JP Morgan to make the case that he and his team had built a valuable late-stage pipeline capable of churning out more than 10 blockbusters in the next 5 years.

And then, just days later, one of the cancer drugs he bet big on as a top prospect — bintrafusp, partnered with Merck KGaA — failed its first pivotal test in non-small cell lung cancer.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Fast on Glax­o­SmithK­line's heels, Au­rinia wins OK to steer a sec­ond lu­pus nephri­tis drug straight to the mar­ket

GlaxoSmithKline’s Benlysta isn’t alone in the small circle of approved lupus nephritis drugs anymore.

Little Aurinia Pharmaceuticals has gotten the green light from the FDA to start marketing its first and only program, voclosporin, under the brand name Lupkynis — something CEO Peter Greenleaf says it’s been ready to do since December.

Regulators went right down to the wire on the decision, keeping the company and the entire salesforce it’s already assembled on its toes.

Eli Lil­ly's an­ti­body cuts risk of Covid-19 by up to 80% among the most vul­ner­a­ble — but will it have a place next to vac­cines?

Eli Lilly says bamlanivimab lowered the risk of contracting symptomatic Covid-19 in a first-of-its-kind trial involving nursing home residents and staff, paving the way for a new option to protect against the virus.

But how big of an impact it might have, and what role it will play, at a time vaccines are being rolled out to the exact population it is targeting still remains unclear.

Among 965 participants in the study — all of whom tested negative for the coronavirus at baseline — the number of symptomatic cases reported in the bamlanivimab arm was 57% lower than that in the placebo arm (odds ratio 0.43, p=0.00021). In addition to that primary endpoint, all secondary endpoints reached statistical significance.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

Janet Woodcock (AP Images)

End­points poll: Janet Wood­cock takes the (in­ter­im) helm at the FDA. And a large ma­jor­i­ty of our read­ers want her to stay there

It’s official: Janet Woodcock is now the acting chief of the FDA.

And — according to an Endpoints poll — most industry readers would like her to stay there, although a significant minority is strongly opposed.

To recap: Joe Biden is reportedly choosing between Woodcock and former deputy FDA commissioner Joshua Sharfstein as his nominee for the permanent position. Given their respective track records, the decision is set to determine the agency’s lodestar for years to come.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

An Endpoints Zoom meeting; and the email header employees will see if your company is a Premium subscriber

What’s next for End­points — and how to sup­port our in­de­pen­dent bio­phar­ma news mis­sion

The firehose of biopharma news is gushing these days.

That’s why broader and deeper is the theme for 2021 at Endpoints. You can expect new coverage outside our core R&D focus, with deeper reporting in some key areas. When John Carroll and I launched Endpoints nearly five years ago, we were wading in waist-high waters. Now we’re a team of 25 full-time staffers (and growing) with plans to cover the flood of biopharma news, Endpoints-style.

Charlie Fuchs, Roche and Genentech global head of product development for oncology and hematology (Yale Cancer Center)

Yale can­cer spe­cial­ist Char­lie Fuchs tapped as new glob­al de­vel­op­ment chief for Roche/Genen­tech

Roche and their big sub Genentech have just recruited a top cancer specialist at Yale to head up global product development in oncology and hematology.

I just got word that the pharma giant, which leads one of the most active cancer research operations in the world, recruited Charlie Fuchs, director of the Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital. He’ll join the global operation March 1 and will be based in South San Francisco, where Genentech is based.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

Jonathan Weissman (MIT)

Can a new CRISPR tech­nique un­lock the se­crets of how can­cer spreads?

Jonathan Weissman’s team watched the cancer cells spread across the doomed mouse. Engineered with a bioluminescent enzyme, they appeared in scans first as a small navy blue diamond lodged near the heart; a week later, as a triangle splayed across the mouse’s upper body, with streaks of green and two distinct bright red hubs of activity. By day 54, the mouse resembled a lava lamp.

The images would have been familiar to any cancer biologist, but they didn’t actually tell you much about what was going on: why the cancer was metastasizing or which cells were responsible. For that, Weissman’s team had designed a new tool. Inside the original navy blue diamond, they had engineered the microbiological equivalent of an airplane’s black box — a “molecular recorder” that, after the mouse’s death, could allow them to extract the cells and wind back intimate footage of a single cancer’s ascent.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.

Glax­o­SmithK­line scraps a LAG3 study, mark­ing an­oth­er fail­ure for the pipeline af­ter a crit­i­cal set­back

Another gap has appeared in GlaxoSmithKline’s pipeline.

Friday morning the Australian biotech Immutep put out word that Hal Barron’s R&D group at GSK had decided to scrap a Phase II proof-of-concept study in ulcerative colitis for their anti-LAG3 therapy GSK2831781. According to the biotech, the program didn’t survive an interim review.

The trial was stopped by GSK based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trial’s Data Review Committee. GSK is conducting further reporting, assessment and analyses of the efficacy and safety data and evaluating the biology to determine next steps for the GSK2831781 development program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,400+ biopharma pros reading Endpoints daily — and it's free.